Cart
sales@molnova.com
Sodium sulfadiazine
CAS No. 547-32-0
Sodium sulfadiazine( —— )
Catalog No. M18781 CAS No. 547-32-0
Sodium Sulfadiazine is a sodium salt form of sulfadiazine, an intermediate-acting bacteriostatic, synthetic sulfanilamide derivative.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | 37 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSodium sulfadiazine
-
NoteResearch use only, not for human use.
-
Brief DescriptionSodium Sulfadiazine is a sodium salt form of sulfadiazine, an intermediate-acting bacteriostatic, synthetic sulfanilamide derivative.
-
DescriptionSodium Sulfadiazine is a sodium salt form of sulfadiazine, an intermediate-acting bacteriostatic, synthetic sulfanilamide derivative.(In Vivo):In this study, the effectiveness of Sulfadiazine sodium and Pyrimetamine for the treatment of mice during acute infection with different atypical T. gondii strains was evaluated. Swiss mice were infected with seven T. gondii strainsl. The infected mice were treated with 10-640?mg/kg per day of Sulfadiazine sodium, 3-200?mg/kg per day of Pyrimetamine, or a combination of both drugs with a lower dosage. A descriptive analysis was used to assess the association between susceptibility to sodium and/or Pyrimetamine and the genotype. The TgCTBr4 and TgCTBr17 strains (genotype 108) presented lower susceptibility to sodium or Pyrimetamine treatment. The TgCTBr1 and TgCTBr25 strains (genotype 206) presented similar susceptibility to PYR but not sodium treatment. The TgCTBr9 strain (genotype 11) was the only strain with high susceptibility to treatment with both drugs .
-
In Vitro——
-
In VivoIn this study, the effectiveness of Sulfadiazine sodium and Pyrimetamine for the treatment of mice during acute infection with different atypical T. gondii strains was evaluated. Swiss mice were infected with seven T. gondii strainsl. The infected mice were treated with 10-640?mg/kg per day of Sulfadiazine sodium, 3-200?mg/kg per day of Pyrimetamine, or a combination of both drugs with a lower dosage. A descriptive analysis was used to assess the association between susceptibility to sodium and/or Pyrimetamine and the genotype. The TgCTBr4 and TgCTBr17 strains (genotype 108) presented lower susceptibility to sodium or Pyrimetamine treatment. The TgCTBr1 and TgCTBr25 strains (genotype 206) presented similar susceptibility to PYR but not sodium treatment. The TgCTBr9 strain (genotype 11) was the only strain with high susceptibility to treatment with both drugs .
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetRetinoid Receptor
-
RecptorOthers
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number547-32-0
-
Formula Weight272.26
-
Molecular FormulaC10H10N4O2S·Na
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (459.12 mM)
-
SMILESNC1=CC=C(C=C1)S(=O)(=O)N([Na])C1=NC=CC=N1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
WYC209
WYC-209 inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs IC50: 0.19 uM). It targets the retinoic acid receptor (RAR).
-
AGN 193109
AGN 193109, a retinoid analog, is a potent and specific antagonist of RARs (Kds: 2 nM, 2 nM, and 3 nM for RARα, RARβ, and RARγ).AGN 193109 is completely RAR specific because it does not bind to or transactivate through any of the RXRs.
-
Bexarotene
Bexarotene is a retinoid specifically selective for retinoid X receptors, used as an oral antineoplastic agent in the treatment of cutaneous T-cell lymphoma.
